Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Puma

- PMLiVE

Pfizer and viral infection specialist ReViral agree on $525m deal

According to the deal, Pfizer will acquire ReViral for a total of up to $525m

- PMLiVE

FDA grants Pfizer/BioNTech expanded EUA for an additional COVID-19 vaccine booster

The second booster authorisation is for those aged 50 years and older to promote high levels of protection against COVID-19 in the most vulnerable groups

- PMLiVE

Pfizer receives Breakthrough Therapy Designation from FDA for RSV vaccine candidate

There are currently no preventative, therapeutic or vaccine options for older adults diagnosed with RSV

- PMLiVE

Pfizer agrees to supply UNICEF with up to 4 million courses of oral COVID-19 treatments

The deal is set to benefit to 95 low- and middle-income countries, pending authorisation or approval

- PMLiVE

AstraZeneca and MSD’s breast cancer drug Lynparza receives FDA approval

An estimated 2.3 million patients were diagnosed with breast cancer in 2020

- PMLiVE

Sanofi experiences setback in phase 2 breast cancer trial

The AMEERA-3 trial tested women aged 18 and over with hormone receptor-positive, HER2-negative advanced breast cancer

- PMLiVE

Pfizer highlights need for fourth dose of COVID-19 vaccine to FDA

While new study published in The Lancet shows COVID-19 mortality rate is almost three times higher than previously thought

- PMLiVE

Pfizer finalises $6.7bn acquisition of Arena Pharmaceuticals

Arena is a clinical stage company developing innovative potential therapies for immuno-inflammatory diseases

- PMLiVE

AbbVie shares positive phase 3 results for migraine drug Qulipta

The impact of chronic migraines on patients can be debilitating

- PMLiVE

Pfizer begins phase 2/3 study of oral COVID-19 treatment in paediatric patients

The phase 2/3 trial involves around 140 patients under the age of 18

- PMLiVE

AbbVie acquires Syndesi Therapeutics in $1bn deal

The deal will allow AbbVie to access Syndesi’s research into Alzheimer's disease

- PMLiVE

Seagen’s Tukysa granted NICE recommendation for breast cancer patients

Approximately 400 patients are expected to benefit from the treatment in England and Wales annually

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links